Casi Pharmaceuticals (CASI): Key FDA Approvals Paramount Catalyst for...

Reply Private New

Next 10 Prev Next

Send PM Follow Ignore

Followers	23
Posts	707
Boards Moderated	0
Alias Born	06/27/2013

TanMan7272

Re: None

Friday, 11/03/2017 12:03:36 PM

Friday, November 03, 2017 12:03:36 PM

Key FDA Approvals Paramount Catalyst for Biotech Run Heading Into November
Tuesday 10/31/2017 08:45 AM ET - PR Newswire via Dow Jones News

MarketNewsUpdates.com News Commentary PALM BEACH, Florida, October 31, 2017 /PRNewswire/ -- The FDA has approved 34 drugs to date in 2017 after approving 22 novel drugs last year. Many biotech and pharma companies have dealt with the drug development process being lengthy and time-consuming along with requiring the utilization of a lot of funds and resources while key drug development events including trial data and regulatory updates are of great importance and could act as major catalysts going forward. Active Biotech stocks are in position to close an already strong 2017 with a bang as the FDA gets set to approve additional drugs heading into next month. Notable biotech leaders in the headlines include: Citius Pharmaceuticals Inc. (NASDAQ: CTXR), MannKind Corporation (NASDAQ: MNKD), Akari Therapeutics Plc (NASDAQ: AKTX), Endocyte Inc. (NASDAQ: ECYT) and Adamas Pharmaceuticals Inc. (NASDAQ: ADMS)